Search

everythinglearnresearchcommunity

for

Search:↓

A user noticed worsening hair loss and is considering treatments. They plan to use finasteride, Rogaine, and a ketoconazole shampoo, and seek advice on their effectiveness and usage.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.

Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.

Effective hair growth treatments include finasteride, minoxidil, dutasteride, and hair transplants, with additional options like microneedling, low-level laser therapy, and PRP showing some benefits. Newer treatments such as GHK-Cu peptides and ketoconazole shampoo are promising, while others like saw palmetto and biotin are less effective unless deficiencies exist.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Oral ketoconazole is discussed as a potential hair loss treatment, but it poses significant health risks like liver damage and adrenal insufficiency. Users suggest safer alternatives like topical anti-androgens or spironolactone, emphasizing the importance of consulting a specialist.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.

A new hair loss treatment reportedly shows a 539% improvement in hair count, but skepticism remains due to unclear placebo results and potential minimal actual hair growth. Many users doubt its effectiveness and market viability, citing high costs and lack of visual proof.

The user tried LLLT laser treatment for hair loss, noticing less hair shedding and thicker hair after six months, emphasizing consistency and gentle scalp care. Other users questioned the authenticity of the post and inquired about the frequency and type of device used.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

Dutasteride is considered safe for conception, with semen concentrations being too low to cause harm. Users discuss switching between dutasteride and finasteride, with some experiencing side effects like acne and heart issues, and advice is given to maintain a consistent treatment regimen.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

A 24-year-old male started taking oral Finasteride 1mg, biotin, and using Nizoral shampoo twice a week for hair loss prevention, reporting no noticeable side effects after nearly three weeks. He notes his hair looks better compared to a month ago.

The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.

Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.

A user switched from finasteride to Avodart (dutasteride) due to the ineffectiveness and poor quality of finasteride in their country. They advise others in similar situations to seek original brands.

The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.

Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

User tried Propecia and topical finasteride but experienced side effects. Switched to Dutasteride and oral Minoxidil, then added CosmeRNA for hair loss treatment.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

Maximum serum DHT suppression for finasteride occurs at 8 hours, while for dutasteride, it occurs within 1 to 2 weeks with daily dosing. Dutasteride mesotherapy will be followed by blood tests to check serum DHT changes.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Dr. Kyle Gillet mentioned on Dr. Andrew Huberman's podcast that dutasteride mesotherapy blocks DHT conversion only in the scalp and is the most promising topical treatment. Users discussed concerns about systemic absorption and the practicality of dutasteride injections.

KX-826 is a potential hair loss treatment, with users discussing its effectiveness compared to finasteride and concerns about its trial results. Some users express skepticism about new treatments, while others discuss the potential of androgen receptor degraders and the need to manage drug resistance.